Bristol Myers Squibb Partners With Pathos AI, Tempus on AI-Driven Alzheimer's Drug Development

• Bristol Myers Squibb entered multi-year collaborations with Pathos AI and Tempus AI to advance AI-driven drug development for neurological diseases.
• The drugmaker leads Pathos's Series E financing, gaining access to its Pathos Foundry AI platform across its broader R&D portfolio.
• Three-year exclusive neuroscience rights aim to improve clinical-trial design for Alzheimer's disease and other neurological conditions.
• Tempus will build a de-identified, longitudinal dataset covering hundreds of thousands of patients with neurological conditions.
• Pathos will license the dataset under a five-year, $55 million agreement to support disease research and more targeted clinical trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20261023830134) on October 23, 2026, and is solely responsible for the information contained therein.